Brukinsa^®
(Siponimod) Novartis

•   Zanubrutinib is a next-generation, highly potent, selective, irreversible Bruton tyrosine kinase (BTK) inhibitor developed for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based on overall response rate (ORR) seen in phase II and I/II clinical trials²

•                   Designed to maximise target occupancy and minimize off-target binding, zanubrutinib may have potential pharmacodynamic and pharmacokinetic advantages over ibrutinib, a standard-of-care BTK inhibitor for B-cell malignancies²

References

1. Drug Office, Department of Health. Brukinsa Capsules 80mg. Available at: https://www. drugoffice.gov.hk/eps/drug/productDetail/en/healthcare_providers/139853. Accessed Aug 29, 2022.  2. Syed YY. Drugs. 2020;80(1):91-97.